Virus portfolio for RSV research and development

Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the Paramyxoviridae family and is known to cause mild to severe respiratory infections. While anyone can be affected, infants, the elderly, and immunocompromised individuals are particularly vulnerable to RSV, experiencing anything from cold-like symptoms to serious respiratory conditions.

The virus exists in two primary subtypes, RSV-A and RSV-B, which circulate concurrently, although RSV-A is generally linked to more severe cases. Seasonal patterns also play a significant role in its spread, with RSV peaking in the colder months in temperate regions but circulating year-round in tropical areas.

In children, RSV is a leading cause of bronchiolitis and pneumonia and accounts for a high rate of hospitalisations, especially among infants under six months. Globally, it is responsible for approximately 100,000 deaths annually in children under five, primarily in developing countries. Among the elderly, RSV poses a significant health risk, especially for those with pre-existing health conditions, leading to an estimated 60,000–160,000 RSV-related hospitalisations and 6,000–10,000 deaths per year in adults aged 65 and above in the United States. Immunocompromised individuals, including those undergoing treatments like chemotherapy, are also at higher risk for severe complications, experiencing more prolonged and intense symptoms.

To better understand RSV, researchers use human challenge models, which involve intentionally exposing volunteers to the virus in controlled settings. This method aids in the quicker and more cost-effective evaluation of potential vaccines and antiviral treatments by mimicking natural infection conditions. The RSV-Memphis-37b strain, isolated in 2001 from a young child, has become an essential tool in these studies, especially in evaluating symptoms, viral loads, and the effectiveness of treatments and vaccines. Recently, hVIVO, a company specialising in human challenge models, has prepared a new GMP batch of this strain, showing enhanced potency in laboratory testing and promising results in clinical trials.

The company is also working on the GMP manufacture of a new RSV-B strain known as RSV-B London. Early findings indicate favourable infection rates and a lack of notable mutations, providing an encouraging foundation for further testing and potential client use. This newly developed RSV-B strain, alongside Memphis-37b, reinforces hVIVO’s portfolio, enabling them to offer reliable virus models to expedite the research and development of RSV treatments.

hVIVO’s RSV strains, such as Memphis and London, serve as robust tools in accelerating RSV research. Developed under strict GMP conditions, these strains demonstrate consistent viral loads and reliable results, making them valuable for evaluating vaccines and antiviral drugs. With its extensive experience in human challenge models, hVIVO supports clients by reducing the time needed for effective RSV research, from preliminary testing to final product development.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Impact of patient perception on vaccine and drug efficacy

    Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from